Calliditas Therapeutics AB (publ) (STO: CALTX)

Market Cap	11.17B
Revenue (ttm)	1.60B
Net Income (ttm)	-480.36M
Shares Out	54.03M
EPS (ttm)	-8.95
PE Ratio	n/a
Forward PE	15.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	126,488
Open	206.20
Previous Close	206.60
Day's Range	204.40 - 206.80
52-Week Range	80.80 - 208.80
Beta	1.48
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About CALTX

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 222
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CALTX

Financial Performance

In 2023, CALTX's revenue was 1.21 billion, an increase of 50.32% compared to the previous year's 802.88 million. Losses were -466.19 million, 13.1% more than in 2022.